Tempo Therapeutics, Inc. (“Tempo”), a leader in tissue engineering and regenerative medicine, has announced the dosing of the first patients in the MOSAIC Trial, a clinical trial for TT101, the company’s lead candidate for tissue regeneration using its proprietary MAP technology.
